Repros Therapeutics (NASDAQ: RPRX) and ArQule (NASDAQ:ARQL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.

Volatility and Risk

Repros Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, ArQule has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Repros Therapeutics and ArQule, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repros Therapeutics 0 1 0 0 2.00
ArQule 0 0 1 0 3.00

Repros Therapeutics currently has a consensus price target of $0.39, suggesting a potential downside of 40.91%. Given Repros Therapeutics’ higher probable upside, analysts plainly believe Repros Therapeutics is more favorable than ArQule.

Valuation & Earnings

This table compares Repros Therapeutics and ArQule’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Repros Therapeutics $50,000.00 522.19 -$17.27 million ($0.50) -1.32
ArQule $4.71 million 30.52 -$22.71 million ($0.40) -4.12

Repros Therapeutics has higher earnings, but lower revenue than ArQule. ArQule is trading at a lower price-to-earnings ratio than Repros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

13.6% of Repros Therapeutics shares are held by institutional investors. Comparatively, 52.1% of ArQule shares are held by institutional investors. 2.5% of Repros Therapeutics shares are held by company insiders. Comparatively, 9.0% of ArQule shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Repros Therapeutics and ArQule’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Repros Therapeutics -4,242.73% -894.22% -230.71%
ArQule N/A -199.07% -86.38%

Summary

ArQule beats Repros Therapeutics on 10 of the 13 factors compared between the two stocks.

Repros Therapeutics Company Profile

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

ArQule Company Profile

ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company’s lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company’s product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Receive News & Ratings for Repros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.